946589-86-2Relevant academic research and scientific papers
Discovery of the CCR1 antagonist, BMS-817399, for the treatment of rheumatoid arthritis
Santella, Joseph B.,Gardner, Daniel S.,Duncia, John V.,Wu, Hong,Dhar, Murali,Cavallaro, Cullen,Tebben, Andrew J.,Carter, Percy H.,Barrish, Joel C.,Yarde, Melissa,Briceno, Stephanie W.,Cvijic, Mary Ellen,Grafstrom, R. Robert,Liu, Richard,Patel, Sima R.,Watson, Andrew J.,Yang, Guchen,Rose, Anne V.,Vickery, Rodney D.,Caceres-Cortes, Janet,Caporuscio, Christian,Camac, Daniel M.,Khan, Javed A.,An, Yongmi,Foster, William R.,Davies, Paul,Hynes, John
, p. 7550 - 7564 (2015/02/18)
High-affinity, functionally potent, urea-based antagonists of CCR1 have been discovered. Modulation of PXR transactivation has revealed the selective and orally bioavailable CCR1 antagonist BMS-817399 (29), which entered clinical trials for the treatment of rheumatoid arthritis.
PRODRUGS OF A PIPERIDINYL DERIVATIVE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
-
, (2011/04/24)
The present application describes prodrugs of the compound of formula (I): or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well a
PIPERIDINYL DERIVATIVE AS A MODULATOR OF CHEMOKINE RECEPTOR ACTIVITY
-
, (2010/01/30)
The present application describes the compound of formula (I): or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune
PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
-
Page/Page column 297, (2008/06/13)
The present application describes substituted piperidinyl modulators of MIP-1α or CCR-1 or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseas
